Dr Cath O'Neill, chief executive of SkinBioTherapeutics PLC (LON:SBTX), tells Proactive they've granted access to their proprietary SkinBiotix technology to a major, global consumer goods company.
Having shared the initial pre-clinical data with a number of interested parties, one potential partner to date has progressed to a material transfer agreement - a standard agreement governing the transfer of material between parties enabling the recipient to assess the technology.
Should the unnamed consumer goods company like what it sees, the arrangement could lead to a commercial arrangement between the two companies.
Meet ANGLE plc, Faron Pharmaceuticals Ltd, Alliance Pharma plc, Clinigen Group PLC and Avacta Group Plc at our event,London, 05 April 2018.Register here >>